Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2022 Earnings Results

Madrigal Pharmaceuticals Misses on EPS — Stock Up 10.98%

Madrigal Pharmaceuticals reported a wider-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by nearly 11% following the earnings announcement, likely due to positive sentiment around their ongoing research and development efforts. Investors may be encouraged by management's focus on their pipeline despite the EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-4.14	N/A	-10.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their clinical programs. They acknowledged the challenges but emphasized their commitment to innovation.

Management highlighted ongoing research and development efforts.

They expressed confidence in their pipeline despite the EPS miss.

Madrigal Pharmaceuticals Misses on EPS — Stock Up 10.98%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS — Stock Up 10.98%

Key numbers

Management commentary